This company listing is no longer active
Sio Gene Therapies (SIOX) Stock Overview
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SIOX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sio Gene Therapies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$0.50 |
| 52 Week Low | US$0.25 |
| Beta | 1.09 |
| 1 Month Change | 22.88% |
| 3 Month Change | 20.25% |
| 1 Year Change | 5.31% |
| 3 Year Change | -85.60% |
| 5 Year Change | -95.10% |
| Change since IPO | -99.73% |
Recent News & Updates
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Recent updates
Shareholder Returns
| SIOX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 22.9% | 1.2% | 1.6% |
| 1Y | 5.3% | 35.1% | 28.2% |
Return vs Industry: SIOX underperformed the US Biotechs industry which returned 7.9% over the past year.
Return vs Market: SIOX underperformed the US Market which returned 17.5% over the past year.
Price Volatility
| SIOX volatility | |
|---|---|
| SIOX Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SIOX's share price has been volatile over the past 3 months.
Volatility Over Time: SIOX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12 | David Nassif | www.siogtx.com |
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM.
Sio Gene Therapies Inc. Fundamentals Summary
| SIOX fundamental statistics | |
|---|---|
| Market cap | US$34.77m |
| Earnings (TTM) | -US$28.83m |
| Revenue (TTM) | n/a |
Is SIOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIOX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.83m |
| Earnings | -US$28.83m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SIOX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/07 05:42 |
| End of Day Share Price | 2024/02/07 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sio Gene Therapies Inc. is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Yun Zhong | BTIG |
| Jason Butler | Citizens JMP Securities, LLC |